G. Thwaites

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial

Scott A. Prentice, Tom Michael Mitchell, Deborah A. Gilliam, 2018, Lancet.

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

K. Y. Wong, Mohammad A. Qayum, John S. Clouston, 2022, Lancet.

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

K. Y. Wong, Beverley E. Crane, Scott M Elliott, 2021, Lancet.

Impact of immunosuppressive agents on clinical manifestations and outcome of Staphylococcus aureus bloodstream infection - A propensity score matched analysis in two large, prospectively evaluated cohorts.

O. Kuss, V. Fowler, C. Liao, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Vancomycin MIC as a predictor of outcome in MRSA bacteraemia in the UK context.

N. Verlander, D. Livermore, S. Hopkins, 2013, The Journal of antimicrobial chemotherapy.